AnaptysBio (ANAB) News Today $34.00 +0.35 (+1.04%) Closing price 04:00 PM EasternExtended Trading$34.00 0.00 (0.00%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Wedbush Has Bullish Outlook for AnaptysBio FY2025 EarningsOctober 19, 2025 | americanbankingnews.comWedbush Has Positive Forecast for AnaptysBio FY2025 EarningsOctober 17, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Earns Overweight Rating from Analysts at BarclaysOctober 16, 2025 | americanbankingnews.comAnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event - SlideshowOctober 15, 2025 | seekingalpha.comAnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event TranscriptOctober 15, 2025 | seekingalpha.comAnaptysBio (NASDAQ:ANAB) Rating Increased to Strong-Buy at BarclaysOctober 14, 2025 | marketbeat.comBarclays Initiates Coverage of AnaptysBio (ANAB) with Overweight RecommendationOctober 14, 2025 | msn.comAnaptysBio, Inc.: Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025October 13, 2025 | finanznachrichten.deAnaptysBio initiated with an Overweight at BarclaysOctober 13, 2025 | msn.comAnaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025October 13, 2025 | globenewswire.comEquities Analysts Issue Forecasts for AnaptysBio Q3 EarningsOctober 12, 2025 | americanbankingnews.comQ3 EPS Estimates for AnaptysBio Lifted by Leerink PartnrsOctober 11, 2025 | marketbeat.comAnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from AnalystsOctober 8, 2025 | marketbeat.comHighMark Wealth Management LLC Raises Stock Position in AnaptysBio, Inc. $ANABOctober 3, 2025 | marketbeat.comLeerink Partnrs Decreases Earnings Estimates for AnaptysBioOctober 3, 2025 | marketbeat.comGuggenheim Sticks to Their Buy Rating for AnaptysBio (ANAB)October 2, 2025 | theglobeandmail.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9% - Time to Sell?October 2, 2025 | marketbeat.comHC Wainwright Analysts Cut Earnings Estimates for AnaptysBioOctober 2, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Up 8.9% on Analyst UpgradeOctober 1, 2025 | marketbeat.comWedbush Reiterates AnaptysBio (ANAB) Outperform RecommendationOctober 1, 2025 | msn.comHC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy RecommendationSeptember 30, 2025 | msn.comAnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New LevelSeptember 30, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst UpgradeSeptember 30, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Price Target Raised to $59.00 at HC WainwrightSeptember 30, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB)September 30, 2025 | marketbeat.comAnaptysBio, Inc. - Special CallSeptember 29, 2025 | seekingalpha.comAnaptysBio, Inc. (ANAB) (ANAB) Strategic Separation To Maximize Shareholder Value Presentation - SlideshowSeptember 29, 2025 | seekingalpha.comAnaptysBio, Inc. (ANAB) Discusses On Strategic Separation To Maximize Shareholder Value (Transcript)September 29, 2025 | seekingalpha.comAnaptysBio splits operations into two companiesSeptember 29, 2025 | msn.comAnaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14September 29, 2025 | globenewswire.comAnaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026September 29, 2025 | globenewswire.comAssenagon Asset Management S.A. Sells 225,526 Shares of AnaptysBio, Inc. $ANABSeptember 29, 2025 | marketbeat.comAnaptysBio jumps after Englander’s Millennium takes stakeSeptember 25, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Trading Up 9.9% - Still a Buy?September 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases Shares of 96,972 AnaptysBio, Inc. $ANABSeptember 22, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Receives Outperform Rating from WedbushSeptember 17, 2025 | marketbeat.comGoldman Sachs Group Inc. Sells 138,529 Shares of AnaptysBio, Inc. $ANABSeptember 17, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.3% - Here's What HappenedSeptember 16, 2025 | marketbeat.comAnaptysBio falls after data abstract on Lilly’s peresolimabSeptember 16, 2025 | msn.comReaction to peresolimab update ‘seems excessive,’ says TD CowenSeptember 16, 2025 | msn.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comAnaptysBio, Inc. $ANAB Shares Bought by Woodline Partners LPSeptember 13, 2025 | marketbeat.com116,623 Shares in AnaptysBio, Inc. $ANAB Purchased by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comGranahan Investment Management LLC Boosts Stock Holdings in AnaptysBio, Inc. $ANABSeptember 8, 2025 | marketbeat.comPDT Partners LLC Takes $828,000 Position in AnaptysBio, Inc. $ANABSeptember 6, 2025 | marketbeat.comTrexquant Investment LP Boosts Stake in AnaptysBio, Inc. $ANABSeptember 6, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading 5.1% Higher - Should You Buy?September 5, 2025 | marketbeat.comRafferty Asset Management LLC Cuts Stake in AnaptysBio, Inc. $ANABSeptember 5, 2025 | marketbeat.com683 Capital Management LLC Makes New $3.64 Million Investment in AnaptysBio, Inc. $ANABSeptember 4, 2025 | marketbeat.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼-0.070.52▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼126▲ANAB Articles Average Week Get the Latest News and Ratings for ANAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AnaptysBio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Lantheus News Today Viking Therapeutics News Today Mirum Pharmaceuticals News Today Telix Pharmaceuticals News Today ACADIA Pharmaceuticals News Today ADMA Biologics News Today Ascentage Pharma Group International News Today Xenon Pharmaceuticals News Today uniQure News Today Zai Lab News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
